Cardiovascular

Chronic stable CAD: secondary prevention and follow-up cadence

Clinical Overview and When to Suspect Chronic Stable CAD

— ~20 million US adults carry a CCD diagnosis; leading cause of mortality globally.

— Recurrent MI, HF, stroke, and cardiovascular death risk persist for life despite revascularization — secondary prevention is the dominant longitudinal task.

— Exertional chest pressure/tightness, dyspnea on exertion, jaw/arm/epigastric discomfort relieved with rest or nitroglycerin.

— Anginal equivalents (dyspnea, fatigue, nausea) in women, diabetics, elderly, CKD patients.

— Decreased exercise tolerance in a patient with ≥2 ASCVD risk factors (HTN, DM, dyslipidemia, smoking, family hx of premature CAD).

Board pearl: A patient with known CAD who returns to clinic with unchanged exertional angina pattern, no rest symptoms, stable functional capacity is "chronic stable" — the correct answer is almost always optimize medical therapy and reassess, NOT repeat catheterization. ISCHEMIA trial established that routine invasive strategy does not reduce death/MI vs optimal medical therapy in stable disease.

Key distinction: Any new rest pain, crescendo pattern, or pain at lower threshold = unstable angina/ACS workflow, not CCD follow-up.

Definition: Chronic coronary disease (CCD, per 2023 AHA/ACC guideline terminology, replacing "stable ischemic heart disease") encompasses patients with prior MI, prior revascularization (PCI/CABG), stable angina, ischemic cardiomyopathy, or obstructive CAD on imaging without acute features.

Epidemiology and burden:

When to suspect in ambulatory practice:

Pretest probability tools: Use the 2023 AHA/ACC pooled clinical tool or PROMISE/CAD Consortium models incorporating age, sex, symptom typicality, and risk factors before ordering testing.

Step 3 framing: On the exam, CCD vignettes almost always test longitudinal management — what to add, titrate, monitor, and when to follow up — rather than acute diagnosis. Expect questions on guideline-directed medical therapy (GDMT) intensification, lipid goals, BP targets, antiplatelet duration, and rehab referrals.

Presentation Patterns and Key History

— Substernal chest discomfort with characteristic quality and duration (2–10 min).

— Provoked by exertion or emotional stress.

— Relieved by rest or sublingual nitroglycerin within ~5 minutes.

— 2 of 3 = atypical; 0–1 = noncardiac.

— Class I: angina only with strenuous activity.

— Class II: slight limitation, angina walking >2 blocks or climbing >1 flight.

— Class III: marked limitation, angina at 1–2 blocks or 1 flight.

— Class IV: angina at rest or any activity.

— Frequency and threshold change: Worsening class (II → III) prompts therapy intensification and consideration of stress testing/angiography.

— Adherence: Missed statin, ACEi, or antiplatelet doses; cost barriers; pill burden.

— Tobacco, alcohol, recreational drug use (cocaine, methamphetamine — vasospasm risk).

— Sexual activity, sildenafil/PDE5 use — contraindication with nitrates within 24h (48h for tadalafil).

— Sleep: OSA symptoms (snoring, witnessed apneas, daytime somnolence) — undertreated OSA worsens HTN and angina.

— Depression and PHQ-9 screening: Depression doubles cardiac mortality post-MI; screen at every CCD visit per AHA.

— Functional status / 6-minute walk equivalent and cardiac rehab participation.

Step 3 management: When a known-CAD patient reports angina now occurring at one flight of stairs instead of three, this is a change in pattern — escalate evaluation (repeat stress imaging or coronary angiography depending on prior data), do not simply uptitrate beta-blocker without reassessment.

Board pearl: Always document the CCS class at every visit — exam stems use a worsening class as the trigger to act.

Classic stable angina criteria (all 3 = typical):

CCS (Canadian Cardiovascular Society) functional class — memorize for exam:

History elements that change management:

Family and social history: Premature CAD (<55 M, <65 F first-degree), familial hypercholesterolemia, occupational exertion demands, driving (commercial license implications).

Physical Exam Findings and Hemodynamic Assessment

— BP both arms at initial visit; target <130/80 mmHg in CCD per 2017 ACC/AHA and reaffirmed 2023 CCD guideline.

— HR resting goal ~55–65 bpm on beta-blocker if tolerated and symptomatic.

— BMI, waist circumference; weight trajectory.

— Carotid bruits → suggests polyvascular disease, consider duplex if symptoms.

— JVP, S3 (LV dysfunction), S4 (LV stiffness from prior MI/ischemia), displaced PMI.

— Murmurs: aortic stenosis can mimic anginal pattern — late-peaking systolic murmur at RUSB radiating to carotids; ischemic MR (apical holosystolic) post-MI.

— Peripheral pulses, ABI if claudication or diminished pulses → PAD coexists in ~30% of CCD.

— Rales, elevated JVP, hepatojugular reflux, lower-extremity edema → HF overlay.

— Pulsus alternans, hypotension, cool extremities → low-output state, not "stable."

— Gait speed <0.8 m/s, grip strength, FRAIL scale — frailty changes the risk-benefit of intensive lipid lowering, anticoagulation, and revascularization.

CCS pearl: In a CCS case for outpatient CAD follow-up, on the first visit order: vital signs, full cardiac/vascular exam, BMI, ECG, lipid panel, HbA1c, BMP, CBC, urine albumin-to-creatinine ratio, and PHQ-2/PHQ-9. Then schedule a return visit at 4–12 weeks to assess therapy response.

Key distinction: Resting tachycardia in a CCD patient on maximal beta-blocker should raise suspicion for anemia, hyperthyroidism, occult HF, or nonadherence — not just "uncontrolled CAD." Work up the cause before adding more rate control.

General/vitals:

Cardiovascular exam:

Signs of decompensation requiring escalation:

Hyperlipidemia stigmata: Xanthelasma, corneal arcus (premature in young patients suggests FH), tendon xanthomas.

Diabetes/metabolic exam: Acanthosis nigricans, monofilament foot exam annually in diabetics with CCD.

Functional/frailty assessment in elderly CCD:

Diagnostic Workup — Initial Labs, ECG, Biomarkers

— Lipid panel: fasting or nonfasting; recheck 4–12 weeks after statin initiation/titration, then every 3–12 months.

— HbA1c annually (every 3–6 months if diabetic) — target individualized, generally <7% in most CCD patients without frailty.

— BMP/eGFR — baseline and annually; more often with ACEi/ARB/diuretic/SGLT2i titration or CKD.

— CBC — anemia worsens angina; iron studies if low.

— TSH — if symptoms, AFib, new HF, or initiating amiodarone.

— LFTs — baseline before statin; routine surveillance NOT required unless symptoms.

— CK only if myalgias suggesting statin myopathy.

— Urine ACR annually in DM, HTN, CKD — informs ACEi/ARB and SGLT2i decisions.

— Lp(a) once in a lifetime per 2023 CCD guideline (Class 2a) — identifies residual genetic risk.

— Baseline 12-lead at diagnosis and with any symptom change.

— Routine annual ECG in asymptomatic stable CAD is not recommended (low yield, USPSTF and Choosing Wisely).

— Repeat with new symptoms, new medication that prolongs QT, or arrhythmia concern.

— High-sensitivity troponin only for suspected ACS — not a screening test in stable patients.

— BNP/NT-proBNP if HF symptoms or to risk-stratify in mixed CAD/HF.

Board pearl: Ordering routine annual stress tests or ECGs in asymptomatic post-PCI/post-CABG patients is low-value care — Choosing Wisely (ACC) explicitly recommends against it. The right answer on Step 3 is symptom-driven testing.

Step 3 management: A stable CCD patient on a statin returns at 6 weeks with LDL 95 (goal <70). Action: add ezetimibe, recheck lipids in 4–12 weeks; do not stop the statin.

Baseline and annual labs in established CCD:

ECG:

Biomarkers:

Other useful baseline tests: Echocardiogram for LVEF if not done within ~2 years or with new symptoms/exam changes; informs ICD candidacy and HF therapy.

Diagnostic Workup — Advanced and Confirmatory Studies

— New or worsening symptoms despite GDMT.

— Pre-operative risk stratification only if it would change management AND functional capacity <4 METs with elevated surgical risk.

— NOT for routine surveillance.

— Exercise ECG: Patient can exercise, baseline ECG interpretable (no LBBB, no paced rhythm, no LVH with strain, no digoxin, no ST changes ≥1 mm). Cheap, first-line if eligible.

— Stress echo or stress nuclear (SPECT/PET): Uninterpretable ECG, prior revascularization, need for localization/quantification of ischemia, or to assess viability.

— Pharmacologic stress (regadenoson, dobutamine): Cannot exercise (poor functional capacity, severe arthritis, PAD). Avoid regadenoson/adenosine in severe reactive airway disease and high-grade AV block; avoid dobutamine in severe HTN, recent ACS, serious arrhythmia.

— Coronary CT angiography (CCTA): Increasingly first-line for low-to-intermediate pretest probability symptomatic patients; excellent NPV. Per 2023 CCD guideline, CCTA is reasonable in symptomatic patients without prior testing.

— Cardiac MRI: Viability, scar quantification, complex cases.

— Indicated when noninvasive testing shows high-risk features (large ischemic burden, LV dysfunction with ischemia, hemodynamic compromise) or symptoms refractory to optimal medical therapy.

— FFR/iFR during ICA to assess physiologic significance of intermediate lesions (50–70%); revascularize only if FFR ≤0.80 or iFR ≤0.89.

Key distinction: ISCHEMIA trial — in stable CAD with moderate-to-severe ischemia, invasive strategy did NOT reduce death/MI vs optimal medical therapy but did improve angina-related QoL. Translation: revascularize for symptoms, not just ischemia burden, in chronic stable disease (excluding left main, EF<35%, recent ACS).

Board pearl: Left main ≥50% or 3-vessel disease with proximal LAD + diabetes → CABG preferred over PCI for mortality benefit.

Stress testing indications in known CCD:

Modality selection:

Invasive coronary angiography (ICA):

High-risk stress findings: ≥10% ischemic myocardium, multi-territory defects, LV dilation with stress, drop in EF ≥10%, ST depression at low workload, Duke treadmill score ≤ –11.

Risk Stratification and First-Line Management Logic

— A ntiplatelet/Antianginal/ACEi

— B eta-blocker/BP control

— C holesterol/Cigarettes

— D iet/Diabetes

— E xercise/Education (cardiac rehab)

— Are symptoms controlled (CCS class, frequency of SL nitro use)?

— Are risk factors at target (BP <130/80, LDL <70 — ideally <55 if very high risk, HbA1c individualized, tobacco-free)?

— Is the patient on guideline-mandated therapies (statin, antiplatelet, ACEi/ARB if indicated, beta-blocker if indicated)?

— Are there new high-risk features (HF symptoms, arrhythmia, change in functional capacity)?

— Very high-risk ASCVD (2018 ACC/AHA): history of multiple major ASCVD events OR 1 major event + multiple high-risk conditions (age ≥65, FH, prior CABG/PCI, DM, HTN, CKD, smoking, persistently elevated LDL ≥100 despite max statin+ezetimibe, HF) → LDL goal <55 mg/dL, add PCSK9 inhibitor if not achieved on statin+ezetimibe.

— Polyvascular disease (CAD+PAD or CAD+stroke): consider rivaroxaban 2.5 mg BID + aspirin 81 mg (COMPASS trial) for additional ischemic risk reduction, weighing bleeding risk.

Step 3 management: When a vignette lists CCD + T2DM + HbA1c 7.4% on metformin, the correct next step is adding empagliflozin or liraglutide, not sulfonylurea or basal insulin — exam tests the cardioprotective add-on.

Board pearl: "Optimal medical therapy" on the boards means statin + antiplatelet + BP control + lifestyle, plus beta-blocker/ACEi/SGLT2i where indicated by comorbidity. Missing any of these is the wrong answer choice.

Goal of CCD management = ABCDE framework:

Risk stratification at every visit asks 4 questions:

Who needs more than baseline therapy?

Diabetes + CCD: Prefer SGLT2 inhibitor (empagliflozin, dapagliflozin) and/or GLP-1 receptor agonist (liraglutide, semaglutide, dulaglutide) — both have proven cardiovascular outcome benefit independent of glucose lowering.

Pharmacotherapy — First-Line Regimen for Secondary Prevention

— Aspirin 75–100 mg daily lifelong in all CCD patients without contraindication.

— Clopidogrel 75 mg daily is acceptable monotherapy if aspirin-intolerant.

— DAPT duration after PCI in stable CAD: aspirin + P2Y12 inhibitor (clopidogrel typically) for 6 months after DES, then aspirin alone. Can shorten to 1–3 months in high bleeding risk; can extend if high ischemic and low bleeding risk.

— Post-ACS DAPT: 12 months default (ticagrelor or prasugrel preferred during this phase), then transition to aspirin monotherapy.

— High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) for all CCD patients ≤75 yrs; moderate-intensity acceptable >75 or with intolerance.

— Goal LDL <70 mg/dL (Class 1); <55 mg/dL in very high-risk ASCVD (Class 2a, 2023 CCD).

— Add ezetimibe if LDL not at goal; then PCSK9 inhibitor (evolocumab, alirocumab) or inclisiran or bempedoic acid if still above goal.

— Icosapent ethyl 2 g BID if TG 150–499 on statin (REDUCE-IT) — reduces CV events.

— ACEi or ARB in CCD + HTN, DM, LVEF ≤40%, or CKD (Class 1). Reasonable in all CCD (Class 2a).

— Indicated for angina symptom control and for 3 years post-MI (especially with reduced EF or HF). Beyond 3 years post-MI with preserved EF and no angina, routine continuation is no longer strongly indicated per 2023 guideline — a notable update.

— Add long-acting nitrate, amlodipine/diltiazem, or ranolazine (useful when HR/BP limit beta-blocker uptitration).

— Sublingual NTG 0.3–0.4 mg PRN; teach patient to call EMS if not relieved in 5 min after one dose.

Board pearl: Don't combine beta-blocker + nondihydropyridine CCB (verapamil/diltiazem) routinely — bradycardia and heart block risk. Use amlodipine if a CCB add-on is needed.

Antiplatelet therapy:

Lipid-lowering:

RAAS blockade:

Beta-blockers:

Antianginals (when symptoms persist):

Influenza vaccine annually and COVID-19/pneumococcal per CDC schedule — reduces CV events.

Procedures and Revascularization in Chronic Stable CAD

— Refractory angina despite optimal medical therapy with ≥2 antianginal classes.

— Left main stenosis ≥50% → CABG (preferred) or PCI in selected anatomy.

— Multivessel disease + LVEF ≤35% → CABG improves survival (STICH).

— 3-vessel disease, especially with proximal LAD and diabetes → CABG > PCI (FREEDOM trial in diabetics).

— High-risk noninvasive findings with significant ischemic burden in a patient who is a procedural candidate.

— SYNTAX score (anatomic complexity), comorbidities, frailty, diabetes, LV function, patient preference. Heart Team discussion required for left main and complex multivessel disease.

— Continue aspirin.

— Hold metformin if contrast load and eGFR <60 (risk of lactic acidosis if AKI).

— Hold SGLT2 inhibitors 3–4 days before to avoid euglycemic DKA.

— Statin pretreatment reduces periprocedural MI.

— Clinic visit at 2–4 weeks to confirm DAPT adherence, access site healing, and resumption of activity.

— Cardiac rehab referral within 1–3 weeks (Class 1, often missed — high-yield).

— Repeat lipid panel 4–12 weeks after statin titration.

— No routine stress testing in asymptomatic patients post-PCI/CABG.

— Aspirin 81 mg lifelong; many add clopidogrel for 12 months if off-pump or saphenous vein grafts (improves graft patency).

— Aggressive LDL lowering preserves graft patency.

— Sternal precautions 6–8 weeks; driving deferred ~4 weeks.

CCS pearl: After an elective PCI in CCS, schedule a follow-up visit in 2–4 weeks, cardiac rehab referral, lipid panel in 6 weeks, and counsel on DAPT adherence and bleeding precautions — this combination is what the rubric rewards.

Key distinction: Premature DAPT discontinuation = stent thrombosis — a tested catastrophe. If urgent non-cardiac surgery is unavoidable, defer if possible, minimum 1 month after DES, continue aspirin throughout when feasible.

Indications for revascularization in CCD (post-ISCHEMIA era):

PCI vs CABG decision factors:

Periprocedural medication management for elective PCI:

Post-PCI follow-up cadence:

Post-CABG considerations:

Special Populations — Elderly, Renal, and Hepatic Impairment

— Continue secondary prevention statin therapy — benefit persists; moderate-intensity often preferred for tolerability.

— BP target individualized; avoid SBP <120 in frail elderly due to falls and orthostasis.

— Beta-blocker dosing: start low, monitor for bradycardia, fatigue, depression.

— Reassess polypharmacy and deprescribe drugs without clear benefit (e.g., long-term beta-blocker >3 years post-MI in preserved EF without angina).

— Cognitive screening before complex regimens; involve caregivers.

— Consider frailty before revascularization — TAVR/PCI candidacy depends on functional reserve.

— CKD is a CAD risk equivalent; aggressive LDL lowering still indicated (statin ± ezetimibe; PCSK9i if needed).

— Avoid rosuvastatin >10 mg if eGFR <30; atorvastatin needs no renal adjustment.

— ACEi/ARB indicated for albuminuria; expect ≤30% creatinine rise — acceptable if stable.

— SGLT2 inhibitors beneficial down to eGFR ~20 (dapagliflozin, empagliflozin) for CV and renal protection.

— Contrast nephropathy mitigation pre-angiography: hold nephrotoxins, IV isotonic saline, minimize contrast volume.

— Metformin: hold if eGFR <30, dose-reduce if 30–45.

— Mild-moderate liver disease: statins generally safe; decompensated cirrhosis or acute liver failure → hold statin.

— Use baseline LFTs; routine surveillance not required.

— Bleeding risk on antiplatelets is increased in cirrhosis; individualize.

Step 3 management: Elderly CCD patient on atorvastatin 80, amlodipine, metoprolol, ASA, ACEi presents with fatigue, dizziness, SBP 105, HR 52. Action: deprescribe or down-titrate beta-blocker (post-MI >3 years, preserved EF, no angina) — guideline-supported and high-yield.

Board pearl: Statins reduce events in CKD stages 1–4; benefit is less clear in dialysis patients — do not initiate de novo in dialysis, but continue if already on therapy.

Elderly (≥75 years):

Chronic kidney disease (eGFR <60):

Hepatic impairment:

Anemia: Even mild anemia worsens angina threshold; evaluate and treat iron deficiency (oral or IV iron in HF overlap).

Special Populations — Women, Pregnancy, and Younger Adults

— More likely to present with atypical symptoms (dyspnea, fatigue, nausea) and INOCA/ANOCA (ischemia/angina with nonobstructive coronaries) due to coronary microvascular dysfunction or vasospasm.

— Workup: consider coronary reactivity testing (acetylcholine provocation) and CFR/IMR during angiography if microvascular angina suspected.

— Treatment of microvascular angina: beta-blockers, CCBs, statins, ACEi, ranolazine for refractory symptoms.

— Address postmenopausal cardiovascular risk; menopausal hormone therapy is NOT cardioprotective and should not be initiated for CV prevention.

— High-risk; multidisciplinary care (cardio-obstetrics).

— Stop teratogens: ACEi, ARB, statins (historically Category X — newer data suggest lower-risk than thought, but still typically held), spironolactone.

— Continue: low-dose aspirin (safe and beneficial), beta-blockers (labetalol, metoprolol preferred; avoid atenolol — IUGR), CCBs (nifedipine, amlodipine acceptable).

— Anticoagulation if indicated: LMWH preferred; warfarin teratogenic in 1st trimester.

— Mode of delivery decisions individualized; epidural to reduce stress response.

— Postpartum: resume statin after breastfeeding cessation if exclusively nursing; restart ACEi if needed (enalapril and captopril are lactation-compatible).

— Screen for familial hypercholesterolemia (LDL ≥190 untreated, tendon xanthomas, family hx). Cascade screening of first-degree relatives.

— Screen Lp(a) once.

— Substance use: cocaine, methamphetamine, anabolic steroids — directly cause CAD/MI; counsel and refer.

— HIV, chronic inflammatory disease (RA, SLE, psoriasis) — accelerated atherosclerosis; intensify prevention.

Key distinction: INOCA is NOT benign — these patients have elevated MACE risk. Don't dismiss "clean coronaries" with persistent symptoms as noncardiac.

Board pearl: In pregnant CCD patients, labetalol and metoprolol succinate are the beta-blockers of choice; atenolol is avoided due to fetal growth restriction.

Women with CCD:

Pregnancy in women with known CAD:

Younger adults (<55) with premature CAD:

Complications and Adverse Outcomes

— Recurrent MI — most common serious event; abrupt symptom change must trigger ACS workup.

— Heart failure — ischemic cardiomyopathy from accumulated infarcts or chronic ischemia; obtain echo with new dyspnea or exam findings.

— Arrhythmia: AFib (common in CCD; manage rate/rhythm and anticoagulate per CHA₂DS₂-VASc), VT/VF (especially with EF ≤35% — evaluate for ICD).

— Sudden cardiac death — ICD indicated for primary prevention if EF ≤35% NYHA II–III on GDMT ≥3 months, or ≥40 days post-MI.

— Stroke — shared atherosclerotic substrate; intensify prevention.

— PAD progression — claudication, critical limb ischemia.

— Statins: myalgia (~5–10%), rare rhabdomyolysis; check CK only if symptomatic. New-onset diabetes risk small (~0.1%/yr) — benefit outweighs.

— Aspirin/antiplatelets: GI bleed (add PPI if high risk: age >65, prior GI bleed, dual antiplatelet, anticoagulation, NSAID/steroid use), intracranial hemorrhage.

— Beta-blockers: bradycardia, fatigue, ED, depression, bronchospasm (use cardioselective in mild COPD/asthma).

— ACEi: cough (5–20%), angioedema (Black patients higher risk; switch to ARB — but angioedema can recur even with ARB, monitor), hyperkalemia, AKI.

— Nitrates: headache, hypotension, tolerance (need nitrate-free interval 10–12 hours).

— PCSK9 inhibitors: injection-site reactions; very low LDL safe.

— SGLT2i: genital mycotic infections, euglycemic DKA, volume depletion.

Board pearl: Sertraline is the best-studied antidepressant in CAD (SADHART trial — safe and effective post-ACS). Avoid citalopram doses >20 mg in elderly (QT prolongation).

Step 3 management: New AFib in stable CAD patient on aspirin: switch to a DOAC alone (not DOAC + aspirin) once stable >12 months from any stent — combination increases bleeding without ischemic benefit (AFIRE trial).

Disease progression complications:

Therapy-related complications:

Psychosocial complications: Depression, anxiety, PTSD post-MI — screen and treat (SSRIs preferred; avoid TCAs in CAD — pro-arrhythmic).

When to Escalate Care — Consult, Inpatient Triage, ED

— Chest pain at rest >20 minutes, unrelieved by 1 SL NTG.

— New rest angina, crescendo angina, or angina with hemodynamic compromise.

— Syncope, near-syncope with exertion, or palpitations with hemodynamic symptoms.

— Acute dyspnea with signs of pulmonary edema.

— Signs of stroke or acute limb ischemia.

— Worsening CCS class (II → III or III → IV) without acute features.

— New LV dysfunction on echo, new wall motion abnormality.

— High-risk findings on stress testing (large reversible defect, ischemia at low workload, exercise-induced hypotension).

— Recurrent angina despite optimal medical therapy.

— Consideration for ICD/CRT in EF ≤35%.

— Post-revascularization patients in the first year.

— EF ≤40% on GDMT.

— Complex multivessel disease, prior CABG with graft issues.

— Refractory hypertension or polypharmacy management.

— Endocrinology: complex diabetes, suspected FH not at goal on max therapy, secondary HTN.

— Nephrology: eGFR <30, rapidly declining renal function, refractory HTN.

— Psychiatry/behavioral health: depression, anxiety affecting adherence.

— Cardiac rehabilitation: referral after MI, PCI, CABG, stable angina, HF — Class 1 indication, vastly underutilized.

— Sleep medicine: OSA screening (STOP-BANG) in CCD with HTN, AFib, or refractory symptoms.

— Home BP monitoring is standard of care for HTN management — provide log template.

— Remote weight monitoring in HF overlap.

CCS pearl: When in doubt about chest pain in a CCD patient by phone, default to ED evaluation — undertriage is a recurring exam-tested error. Document the conversation.

Board pearl: Cardiac rehab reduces all-cause mortality ~20% and CV mortality ~25% — it is a drug-level intervention and the most commonly missed correct answer.

Send to ED immediately:

Urgent cardiology referral (days to 1–2 weeks):

Routine cardiology co-management (every 6–12 months):

Other consults:

Telehealth and remote monitoring:

Key Differentials — Same-Category (Cardiac) Causes of Chest Pain in CCD Patients

— Rest pain, crescendo pattern, new ST changes, elevated hs-troponin.

— Differentiation from stable angina is the highest-yield call — wrong answer = "follow up in clinic in 1 week."

— Rest pain, often early morning, transient ST elevation, smokers, young women, cocaine users.

— Provocation with acetylcholine or ergonovine diagnostic.

— Treat with CCB ± long-acting nitrate; avoid nonselective beta-blockers (can worsen vasospasm by unopposed alpha).

— Typical angina with nonobstructive coronaries; abnormal coronary flow reserve or microvascular resistance.

— Treat with beta-blockers, CCB, statin, ACEi, ranolazine.

— Angina, syncope, HF; harsh late-peaking systolic murmur radiating to carotids, soft S2, slow-rising pulse.

— Refer for TAVR/SAVR when symptomatic and severe.

— Exertional chest pain, syncope, family history; systolic murmur that increases with Valsalva and standing.

— Beta-blocker first line; avoid nitrates/diuretics that worsen outflow obstruction.

— Sharp, pleuritic, positional (worse supine, better leaning forward), diffuse ST elevation with PR depression.

— Viral prodrome, troponin elevation, regional wall motion abnormalities without obstructive CAD; cMRI diagnostic.

— Tearing pain radiating to back, BP differential between arms, widened mediastinum on CXR; CT angio.

— Dyspnea, orthopnea, PND, edema; elevated BNP, congestion on exam/imaging.

Key distinction: In a known CCD patient, the single most important triage question is "is this pain different from your usual angina — at rest, more frequent, lower threshold?" If yes → ACS pathway.

Board pearl: Variant angina treatment — CCB first, nitrates as adjunct; avoid nonselective beta-blockers and triptans/ergots.

Acute coronary syndrome (UA/NSTEMI/STEMI):

Coronary vasospasm (Prinzmetal/variant angina):

Microvascular angina (cardiac syndrome X / INOCA):

Aortic stenosis:

Hypertrophic cardiomyopathy:

Pericarditis:

Myocarditis:

Aortic dissection:

Heart failure exacerbation:

Key Differentials — Non-Cardiac Causes of Chest Pain

— GERD: burning, postprandial, supine, relieved by antacids/PPIs; can mimic angina and even respond partially to nitrates (smooth muscle relaxation).

— Esophageal spasm: chest pain ± dysphagia; manometry diagnostic; CCBs/nitrates help.

— Peptic ulcer disease, biliary colic, pancreatitis: location and food relationship clarify.

— Pulmonary embolism: pleuritic pain, dyspnea, tachycardia, hypoxia, unilateral leg swelling; Wells score, D-dimer or CTPA.

— Pneumothorax: sudden pleuritic pain, dyspnea, decreased breath sounds.

— Pneumonia: fever, cough, productive sputum, infiltrate.

— Pleuritis: pleuritic, friction rub.

— Costochondritis: reproducible with palpation, history of overuse or recent URI.

— Cervical/thoracic radiculopathy: dermatomal radiation, positional.

— Rib fracture: trauma history, point tenderness.

— Panic disorder/anxiety: episodic, palpitations, paresthesias, sense of impending doom, normal workup — but do not anchor here in a CCD patient without ruling out ACS first.

— Herpes zoster: dermatomal pain preceding vesicles by 1–4 days — classic exam trap.

— Cocaine chest pain: treat with benzodiazepines, nitrates, CCBs; avoid beta-blockers acutely (unopposed alpha vasoconstriction); aspirin and standard ACS workup.

Step 3 management: In a CCD patient with new chest pain, the order of operations is: (1) rule out ACS with ECG + hs-troponin, (2) consider PE/dissection if features suggest, (3) then pursue noncardiac differentials. Skipping step 1 is the wrong-answer trap.

Board pearl: Reproducible chest wall tenderness does not rule out ACS — 7–15% of confirmed MIs have some component of reproducible discomfort. Use the full clinical picture and troponin.

Key distinction: A "GI cocktail" relieving chest pain has no diagnostic value for excluding cardiac etiology — boards explicitly test this misconception.

Gastroesophageal:

Pulmonary:

Musculoskeletal:

Psychiatric:

Dermatologic/neurologic:

Substance-related:

Secondary Prevention and Long-Term Plan

— Tobacco cessation: counsel at every visit (5 A's), offer varenicline, bupropion, NRT, or combination; cessation reduces CV events ~36% within years.

— Diet: Mediterranean or DASH pattern; reduce saturated fat <6% calories, minimize trans fats and added sugars, limit sodium <2300 mg/day (<1500 if HTN).

— Physical activity: ≥150 min/week moderate aerobic OR ≥75 min vigorous, plus 2 days resistance training. Tailored if frail or post-procedure.

— Weight: target BMI 18.5–24.9; even 5–10% weight loss improves lipids, BP, glycemia.

— Alcohol: ≤1 drink/day women, ≤2 drinks/day men; counsel that "moderate alcohol for heart health" is no longer endorsed.

— Sleep: 7–9 hours; screen and treat OSA.

— Aspirin 81 mg daily (or clopidogrel if intolerant).

— High-intensity statin + ezetimibe ± PCSK9i to LDL <70 (or <55 if very high risk).

— ACEi/ARB if HTN, DM, HF, CKD, LVEF ≤40%.

— Beta-blocker if angina, post-MI ≤3 years, or LVEF ≤40%.

— SGLT2i and/or GLP-1 RA in T2DM with CAD.

— Icosapent ethyl if persistent TG 150–499 on statin.

— Colchicine 0.5 mg daily (LoDoCo2) — emerging Class 2b option to reduce residual inflammatory risk; weigh GI side effects.

Board pearl: Smoking cessation is the single highest-yield secondary prevention intervention — bigger relative risk reduction than any single drug.

Step 3 management: At every CCD follow-up, document the "5 A's" for tobacco (Ask, Advise, Assess, Assist, Arrange) — graders look for it.

Lifestyle prescription (Class 1 in all CCD):

Pharmacologic pillars (ABCDE recap):

Vaccinations: influenza annually, COVID-19 per CDC, pneumococcal (PCV20 or PCV15+PPSV23), zoster ≥50, RSV ≥60 if appropriate, Tdap.

Cancer/preventive screening: Don't neglect age-appropriate USPSTF screens — CCD patients live long enough to die of other causes.

Cardiac rehab: Class 1 referral after MI, PCI, CABG, stable angina — 36 sessions over 12 weeks typically covered by Medicare.

Follow-Up Cadence, Monitoring, and Counseling

— Stable, optimized patient: every 4–6 months for clinical assessment; some stable patients with primary care co-management can extend to annual cardiology follow-up.

— After medication change or titration: 2–4 weeks to assess tolerability and response, then 4–12 weeks for biochemical recheck.

— After PCI: clinic visit at 2–4 weeks, then 3 months, then every 6 months in year 1, then annually if stable.

— After CABG: 2 weeks (wound, sternum, meds), 6 weeks (return to activities), 3 months, then 6–12 monthly.

— After ACS: 1 week, 1 month, 3 months, then every 6 months in year 1.

— Symptoms (CCS class, nitro use), functional capacity, adherence, side effects.

— BP, HR, weight, BMI.

— PHQ-2 → PHQ-9 if positive; screen for anxiety.

— Tobacco/alcohol/substance use.

— Medication reconciliation, cost/access barriers.

— Lipid panel 4–12 weeks after titration, then every 3–12 months.

— HbA1c every 3–6 months if diabetic, annually if not.

— BMP/eGFR/K annually, more often on ACEi/ARB/diuretic/SGLT2i.

— LFTs only if symptomatic on statin.

— Annual urine ACR in DM/HTN/CKD.

— Echo every 1–3 years if EF ≤40% or with symptom change; not routine in preserved EF asymptomatic patients.

— No routine stress testing in asymptomatic patients post-revascularization (Choosing Wisely).

— Repeat stress imaging if new/worsening symptoms or to guide therapy escalation.

— Recognize warning signs (rest pain >5 min, unrelieved by 1 NTG → call 911).

— Carry SL NTG; replace yearly; store away from heat/light.

— Medication adherence — pillbox, app reminders, 90-day refills.

— Cardiac rehab participation and home exercise plan.

CCS pearl: In a CCS case, the right follow-up rhythm after stabilizing CAD therapy is: clinic in 4–6 weeks (recheck labs, BP, symptoms) → 3 months (lipid goal assessment, adherence) → 6 months (longitudinal reassessment).

Board pearl: A patient saying "I haven't used my nitro in 6 months" is the best clinical metric of effective angina control.

Visit cadence for chronic stable CAD:

At each visit, assess:

Laboratory monitoring:

Imaging/testing surveillance:

Counseling at every visit:

Ethical, Legal, and Patient Safety Considerations

— In stable CAD, ISCHEMIA data must be disclosed: PCI/CABG does not reduce death or MI vs optimal medical therapy in most stable patients, but improves symptoms. Failure to disclose this is increasingly viewed as inadequate consent.

— Heart Team discussion documented for left main and complex multivessel disease.

— Hospital discharge after MI/PCI/CABG is the single highest-risk transition for readmission and adverse drug events. Required elements:

— Medication reconciliation with explicit changes.

— DAPT duration explicitly documented and communicated to PCP and pharmacy.

— Follow-up appointment scheduled within 7–14 days.

— Discharge summary to PCP within 48–72 hours.

— Patient teach-back of warning signs, NTG use, and rehab plan.

— Missed DAPT instructions are a sentinel-event-level safety failure.

— Private vehicle: typically 1 week post-PCI, 4 weeks post-CABG, 1 month post-MI without complications (varies by state).

— Commercial drivers (FMCSA): more stringent — 3 months post-MI minimum, stress test required for return; report to licensing authority where mandated.

— Pilots and others: similar return-to-duty protocols.

— Use decision aids for ICD primary prevention, PCSK9i initiation (cost), and DAPT duration tradeoffs (ischemia vs bleeding).

— Advance care planning in elderly/frail CCD — discuss code status, ICD deactivation at end of life.

— Black and Hispanic patients have lower rates of statin, rehab, and revascularization referral — actively audit and correct.

— Cost barriers: prescribe generics, 90-day fills, assistance programs for PCSK9i.

— Impaired driving due to syncope or arrhythmia in states with physician reporting laws.

— Substance use disorder when overlapping with occupational safety (e.g., commercial drivers, pilots).

Step 3 management: Patient post-PCI on DAPT requests elective cholecystectomy at 2 months. Action: defer surgery to ≥6 months post-DES if possible, continue aspirin perioperatively, hold P2Y12 inhibitor 5–7 days before with bridging strategy discussion — never stop DAPT silently.

Board pearl: The right answer to "what's the most important thing at discharge after MI?" is almost always medication reconciliation + 7–14 day follow-up + cardiac rehab referral.

Informed consent for revascularization:

Transitions of care — high-risk windows:

Driving and occupational considerations:

Shared decision-making:

Health equity:

Mandatory reporting:

High-Yield Associations and Rapid-Fire Clinical Facts

— CCD + HFrEF → ACEi/ARNI + beta-blocker + MRA + SGLT2i (the 4 pillars).

— CCD + T2DM → SGLT2i and/or GLP-1 RA + statin + ACEi/ARB.

— CCD + AFib + recent stent → triple therapy minimized to ~1 month, then DOAC + clopidogrel to 12 months, then DOAC alone.

— CCD + PAD → consider rivaroxaban 2.5 mg BID + aspirin 81 mg (COMPASS).

— CCD + persistent TG 150–499 on statin → icosapent ethyl.

— CCD + LDL >goal on max statin → ezetimibe → PCSK9i.

— LDL goal CCD: <70 mg/dL; very high-risk: <55 mg/dL.

— BP goal: <130/80 mmHg.

— HbA1c: individualized, typically <7%.

— Cardiac rehab: 36 sessions over 12 weeks, Class 1.

— Aspirin: 81 mg daily indefinitely.

— DAPT after elective DES for stable CAD: 6 months default.

— DAPT after ACS: 12 months default.

— Beta-blocker post-MI with preserved EF and no angina: routine continuation beyond 3 years no longer indicated (2023 update).

— Statin dose: atorvastatin 40–80, rosuvastatin 20–40 for high-intensity.

— ISCHEMIA — invasive ≠ better than OMT for hard endpoints in stable CAD.

— COURAGE — same conclusion, earlier era.

— FREEDOM — CABG > PCI in diabetics with multivessel CAD.

— STICH — CABG benefit in ischemic cardiomyopathy with EF ≤35%.

— COMPASS — low-dose rivaroxaban + aspirin in CAD/PAD.

— REDUCE-IT — icosapent ethyl reduces CV events.

— FOURIER/ODYSSEY — PCSK9 inhibitors reduce events.

— LoDoCo2 — colchicine in chronic CAD.

— EMPA-REG, DAPA-HF, EMPEROR — SGLT2i in CV/HF outcomes.

Board pearl: When a stem includes "CAD + diabetes + HbA1c 7.x on metformin," the answer is almost always add SGLT2 inhibitor or GLP-1 RA — pattern recognition wins.

Drug + condition pairings:

Numbers to memorize:

Trials by name:

Don't forget: Influenza vaccine annually in CCD reduces CV events.

Board Question Stem Patterns

— Patient on atorvastatin 80, LDL 90. Next step? → Add ezetimibe, recheck in 4–12 weeks. PCSK9i comes next if still above goal.

— Patient with class II → class III angina on max BB + statin + ASA + ACEi. Next step? → Stress imaging or coronary angiography to reassess anatomy, especially if not done recently.

— DES placed 2 months ago for stable CAD, needs elective hernia repair. → Defer surgery to at least 6 months post-DES; continue aspirin throughout; hold P2Y12 5–7 days only if surgery cannot wait, after cardiology discussion.

— On aspirin already. → DOAC monotherapy (e.g., apixaban) if >12 months from any stent; DOAC + clopidogrel if within 12 months of stent (drop aspirin early after first month).

— On metformin, A1c 7.5%. → Add empagliflozin or liraglutide/semaglutide for cardiovascular protection.

— Wants stress test "to check." → Do not order; reinforce GDMT, lifestyle, lipid goals, rehab.

— On beta-blocker, EF preserved, no angina. → Down-titrate or stop beta-blocker (2023 guideline supports).

— Wants to start SGLT2i? → Yes, dapagliflozin/empagliflozin appropriate; provides renal and CV protection. Hold metformin if eGFR <30.

— On ACEi, statin, ASA, metoprolol. → Stop ACEi and statin; continue ASA and metoprolol (or switch atenolol to labetalol).

— → Confirm symptoms with washout, try lower dose, switch to rosuvastatin or pravastatin, then ezetimibe, then bempedoic acid; do not abandon LDL lowering.

Step 3 management: The most common wrong answers in CCD vignettes are "repeat stress test in asymptomatic patient" and "discontinue statin for mild myalgia without rechallenge." Recognize and avoid.

Board pearl: Every CCD stem that mentions a missed therapy class (no statin, no ASA, no rehab) is asking you to add it — that's almost always the answer.

Stem pattern 1 — "Stable angina, LDL above goal":

Stem pattern 2 — "Worsening CCS class on optimal therapy":

Stem pattern 3 — "Post-PCI patient asks about elective surgery":

Stem pattern 4 — "CAD + new AFib":

Stem pattern 5 — "CAD + T2DM not at A1c goal":

Stem pattern 6 — "Routine annual visit, asymptomatic post-CABG":

Stem pattern 7 — "Elderly post-MI 5 years ago, fatigue, HR 50":

Stem pattern 8 — "CAD + chronic kidney disease eGFR 35":

Stem pattern 9 — "Pregnant patient with prior MI":

Stem pattern 10 — "Patient declines statin due to muscle aches":

One-Line Recap

Chronic stable CAD is a lifelong disease whose secondary prevention rests on guideline-directed medical therapy — high-intensity statin to LDL <70 (or <55 if very high risk), aspirin, BP <130/80, ACEi/ARB and beta-blocker when indicated, SGLT2i/GLP-1 RA in diabetes, lifestyle change, cardiac rehab, and symptom-driven (not routine) testing — with revascularization reserved for refractory angina or high-risk anatomy.

Board pearl: When the exam describes a stable CAD patient with any therapy "missing" from the ABCDE checklist, the answer is to add it and follow up in 4–12 weeks — that single heuristic answers a large fraction of CCD questions.

Recap bullet 1 — Pharmacology pillars: ASA 81 + high-intensity statin (+ ezetimibe/PCSK9i to target) + ACEi/ARB if HTN/DM/CKD/EF≤40 + beta-blocker if angina or post-MI ≤3 yrs or EF≤40 + SGLT2i/GLP-1 RA in T2DM + icosapent ethyl if TG persistently elevated.

Recap bullet 2 — Testing discipline: No routine stress tests or ECGs in asymptomatic stable patients (Choosing Wisely). Reassess with stress imaging or angiography only when symptoms worsen, functional capacity drops, or new high-risk features emerge. ISCHEMIA: revascularize for symptoms, not ischemia burden alone (excluding left main, EF<35%, ACS).

Recap bullet 3 — Follow-up cadence: Stable optimized patient every 4–6 months; after med titration recheck labs in 4–12 weeks; after PCI visit at 2–4 weeks then 3 and 6 months; after CABG visit at 2 weeks, 6 weeks, 3 months; cardiac rehab referral is Class 1 after every MI, PCI, CABG, and for stable angina.

Recap bullet 4 — Safety and transitions: Discharge after revascularization is the highest-risk handoff — explicit DAPT duration, 7–14 day follow-up, med reconciliation, teach-back of warning signs, and rehab referral are non-negotiable; never stop DAPT silently for elective surgery within 6 months of DES; screen for and treat depression, OSA, tobacco use at every visit.